EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021

Planet edap Inc.
Nov 10,2021

EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021

Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET

LYON, France, November 10, 2021 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2021 after the markets close on Wednesday, November 17, 2021.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, Chief Executive Officer of EDAP U.S.A., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, November 18, 2021. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, November 18th@ 8:30am Eastern Time
Domestic:                877-451-6152
International:           201-389-0879
Passcode:                13724088
Webcast:                 https://viavid.webcasts.com/starthere.jsp?ei=1503943&tp_key=7d846a9985


A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Blandine Confort
Investor Relations / Legal Affairs
+33 4 72 15 31 50

Investor Contact
John Fraunces
LifeSci Advisors, LLC